-
公开(公告)号：US11904003B2
公开(公告)日：2024-02-20
申请号：US18185661
申请日：2023-03-17
发明人： Jens Hukelmann , Heiko Schuster , Ricarda Hannen , Christoph Schraeder , Jens Fritsche , Franziska Hoffgaard , Daniel Johannes Kowalewski , Oliver Schoor
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC分类号： A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11897934B2
公开(公告)日：2024-02-13
申请号：US17172621
申请日：2021-02-10
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Lea Stevermann
IPC分类号： C07K14/70 , C07K14/74 , G01N33/569 , A61K39/00 , C07K16/28 , A61K45/06 , A01N37/46 , C07K14/725 , C12Q1/6886 , C07K14/47 , C07K16/30 , A61K38/08 , C07K7/02 , C07K7/06 , G01N33/566 , C07K16/18 , C12N5/0783 , C12N9/64 , C07K14/00 , A61K38/17 , G01N33/50 , A61K38/06 , A61K38/00
CPC分类号： C07K14/70539 , A01N37/46 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12Q1/6886 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , A61K38/00 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N2501/998 , C12N2502/11 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N2333/04 , G01N2333/7051 , G01N2333/70503 , G01N2333/70539 , G01N2500/10
摘要： A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.
-
公开(公告)号：US11890333B2
公开(公告)日：2024-02-06
申请号：US17390583
申请日：2021-07-30
发明人： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC分类号： C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
CPC分类号： A61K39/0011 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/2833 , C12Q1/6886 , A61K2039/5158 , A61K2039/572 , A61K2039/80 , C07K2319/33 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
24.发明公开公开(公告)号：US20240016911A1
公开(公告)日：2024-01-18
申请号：US18455685
申请日：2023-08-25
发明人： Jens HUKELMANN , Heiko SCHUSTER , Ricarda HANNEN , Christoph SCHRAEDER , Jens FRITSCHE , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR
IPC分类号： A61K35/17 , C07K14/725 , A61K45/06 , A61P37/04
CPC分类号： A61K35/17 , C07K14/7051 , A61K45/06 , A61P37/04
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
25.发明公开公开(公告)号：US20240016909A1
公开(公告)日：2024-01-18
申请号：US18451883
申请日：2023-08-18
发明人： Jens HUKELMANN , Heiko SCHUSTER , Ricarda HANNEN , Christoph SCHRAEDER , Jens FRITSCHE , Franziska HOFFGAARD , Daniel Johannes KOWALEWSKI , Oliver SCHOOR
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC分类号： A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11872270B2
公开(公告)日：2024-01-16
申请号：US17149397
申请日：2021-01-14
发明人： Colette Song , Linus Backert , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
CPC分类号： A61K39/0011 , A61P35/00 , C07K7/06 , C07K16/2833 , C07K16/30 , A61K2039/5158 , C07K2317/32
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US11859009B2
公开(公告)日：2024-01-02
申请号：US17934303
申请日：2022-09-22
发明人： Gabriele Pszolla , Martin Hofmann , Meike Hutt , Sebastian Bunk , Felix Unverdorben , Frank Schwoebel , Dominik Maurer , Maike Jaworski , Claudia Wagner , Florian Schwoerer , Heiko Schuster
CPC分类号： C07K16/30 , C07K16/2809 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/73 , C07K2317/92
摘要： The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US11833195B2
公开(公告)日：2023-12-05
申请号：US17489557
申请日：2021-09-29
发明人： Jens Hukelmann , Heiko Schuster , Ricarda Hannen , Christoph Schraeder , Jens Fritsche , Franziska Hoffgaard , Daniel Johannes Kowalewski , Oliver Schoor
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/74
CPC分类号： A61K39/0011 , A61P35/00 , C07K14/705 , C07K14/70539 , A61K39/00 , A61K2039/5158
摘要： The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11833193B2
公开(公告)日：2023-12-05
申请号：US17149241
申请日：2021-01-14
发明人： Colette Song , Linus Backert , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
CPC分类号： A61K39/0011 , A61P35/00 , C07K7/06 , C07K16/2833 , C07K16/30 , A61K2039/5158 , C07K2317/32
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
30.发明授权公开(公告)号：US11826409B2
公开(公告)日：2023-11-28
申请号：US17320938
申请日：2021-05-14
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Phillip Mueller , Julia Leibold , Valentina Goldfinger
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/725 , C07K16/30 , C12N5/0783 , C12N15/115 , C12Q1/6886 , G01N33/574 , G01N33/68
CPC分类号： A61K39/0011 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K16/30 , C12N5/0636 , C12N15/115 , C12Q1/6886 , G01N33/5748 , G01N33/6848 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2319/00 , C12N2310/16 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/57407 , G01N2570/00 , G01N2800/52
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
1120 条记录 (耗时 0.04 秒)
